Apitegromab

Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy[1][2].

Product Specifications

CAS Number

[2278276-46-1]

Product Name Alternative

SRK-015

UNSPSC

12352203

Target

TGF-beta/Smad

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/apitegromab.html

Purity

99.51

Solubility

10 mM in DMSO

Smiles

[Apitegromab]

Molecular Weight

(145.06 kDa)

References & Citations

[1]Doreen Barrett, et al. A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015) : A Potential Treatment for Spinal Muscular Atrophy. Adv Ther. 2021 Jun;38 (6) :3203-3222. |[2]Welsh BT, et al. Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease. Int J Toxicol. 2021 Jul-Aug;40 (4) :322-336.